Dapagliflozin FDA approval date

The FDA approved Dapagliflozin on 8 Jan 2014.

FDA approval date
8 Jan 2014

Drug identity checked against registry records

Included trials

TrialSponsorPhaseStatusPrimary completion
A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA NephropathyNCT03762850TVTXPhase 3Completed2023-08-07Actual

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2014-01-08DayDapagliflozinFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "NDA202293", "applicant_as_listed_by_fda": "ASTRAZENECA AB", "brand_names": ["FARXIGA"], "active_ingredients": ["DAPAGLIFLOZIN"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20140108", "matched_on": "drug name equals FDA sole active ingredient"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026